NICE approves new diabetes treatment for NHS prescribing

Ertugliflozin (Steglatro), the newest sodium glucose co-transporter 2 (SGLT2) inhibitor, has been approved by NICE for routine NHS prescribing in patients with type II diabetes.

Ertugliflozin is the latest SGLT2 inhibitor approved for routine NHS prescribing in type II diabetes. | CNRI/SCIENCE PHOTO LIBRARY
Ertugliflozin is the latest SGLT2 inhibitor approved for routine NHS prescribing in type II diabetes. | CNRI/SCIENCE PHOTO LIBRARY

NICE recommends ertugliflozin monotherapy as an option for treating type II diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:

Ertugliflozin is also recommended by NICE for use in combination with metformin as an option when:

  • a sulfonylurea is contraindicated or not tolerated or
  • the person is at significant risk of hypoglycaemia or its consequences.

NICE's recommendation was based on the results of three pivotal trials, VERTIS-MONO, VERTIS-MET and VERTIS-FACTORIAL, in which patients treated with ertugliflozin as monotherapy or as dual therapy with metformin showed significant reductions in HbA1c from baseline to week 26 compared with patients given placebo.

In its assessment, NICE concluded that the acquisition cost of ertugliflozin is lower than that of other SGLT2 inhibitors while the overall health benefits are similar.

Want news like this straight to your inbox?
Sign up for our bulletins

Yejin Yang recommends

MIMS Diabetes Clinic

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...